Neuroone Medical Technologies is trading at $1.05, down 6.25%, with no clear company-specific catalyst identified for the October 12 decline. - A report said shares were down 11.61% pre-market, also without a clear catalyst. - The latest company announcement, an October 8 Dartmouth research subaward, provides approximately $200,000 through April 2027 and does not explain the decline. - Major indices were mixed, each moving less than 0.5%, offering no clear broad-market explanation.